STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability
Approximately 30% of human cancers harbor oncogenic gain-of-function mutations in KRAS. Despite interest in KRAS as a therapeutic target, direct blockade of KRAS function with small molecules has yet to be demonstrated. Based on experiments that lower mRNA levels of protein kinases, KRAS-dependent c...
Main Authors: | , , , , , , , , , , , |
---|---|
Other Authors: | |
Format: | Article |
Language: | en_US |
Published: |
National Academy of Sciences
2012
|
Online Access: | http://hdl.handle.net/1721.1/72564 https://orcid.org/0000-0002-7203-4299 |